Citations

Clear

948 citation(s) found for "Li, Bryan".

Imaging solute transportation along the posterior lymphatic pathway in the ocular glymphatic system in healthy human participants
Wen, Xuehua , Sun, Yuanqi, Li, Yinghao, Paez, Adrian , Varghese, Jacob , Knutsson, Linda, Zijl, Peter C.M. Van, Graley, Christina R, Bakker, Arnold, Ward, Bryan K., Kashani, Amir H. , Sun, Yuanqi , Zhou, Xinyi Yedda , Li, Yinghao , Varghese, Jacob, Pillai, Jay J. , Knutsson, Linda , Zijl, Peter C.M. van , Leigh, Richard J. , Kamson, David , Saidha, Shiv , Bakker, Arnold , Ward, Bryan Kevin

Mayo Clinic

No container title available | April 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.03.26349283 | PMID 42006786 Get It

Abstract Background Recently, a posterior pathway for fluid drainage from the retina to the meningeal lymphatics in the optic nerve (ON) sheath was identified in rodents using intravitreal imaging tracers directly injected into the ocular-globe. Fluid and solute clearance along this pathway may be associated with many diseases. However, intravitreal tracers are rarely used in clinical imaging. As intravenous Gadolinium-based-contrast-agent (GBCA) can enter the globe via the blood-ocular-barriers, it may provide an alternative approach to image this pathway. Purpose To establish a clinically feasible intravenous GBCA-based MRI approach for tracking fluid and solute transport along the posterior lymphatic pathway in the ocular glymphatic system. Materials&Methods This prospective study was conducted from March 2021 to September 2022 in healthy participants. Dynamic-susceptibility-contrast-in-the-CSF (cDSC) MRI was performed before, immediately and 4 hours after intravenous-GBCA administration to track GBCA distribution in aqueous humor (AH) and cerebrospinal fluid (CSF) in regions-of-interest (ROIs) in the globe (anterior-cavity, vitreous-body), in the intraorbital and extraorbital ON, and in the intracranial CSF space proximal to the ON (chiasmatic-cistern, interpeduncular-cistern). Kruskal–Wallis tests with post-hoc Dunn’s tests were used for group comparisons. Results Sixteen healthy participants (mean age±SD: 51±21 years, 5 men) were recruited. Intravenous-GBCA enhancement was observed in all ROIs immediately after injection. At 4-hour-post-GBCA, the vitreous body showed a trend of smaller enhancement area (55±11% versus 49±11%, P =.14) and lower GBCA-concentration (0.044±0.014 versus 0.028±0.010 mmol/L, P =.07) compared to immediate-post-GBCA. The intraorbital ON showed more widespread enhancement (39±5% versus 59±6%, P =.01) and significantly higher GBCA-concentration (0.023±0.009 versus 0.059±0.015 mmol/L, P <.001) at 4-hour-post-GBCA. Conclusion Dynamic fluid and solute transportation along the posterior lymphatic pathway in the ocular glymphatic system in healthy participants was measured by tracking intravenous-GBCAs entering the globe via the blood-ocular-barriers using cDSC-MRI. Summary Statement Dynamic fluid and solute transportation along the posterior lymphatic pathway in the ocular glymphatic system in healthy participants was measured by tracking intravenous-Gadolinium-based-contrast-agents entering ocular-globe via blood-ocular-barriers using dynamic-susceptibility-contrast-in-the-CSF (cDSC)-MRI. Key Results In this prospective study of sixteen participants, Gadolinium-based-contrast-agent (GBCA)-induced signal changes were detected in the aqueous-humor and cerebrospinal fluid immediately following intravenous administration using dynamic-susceptibility-contrast-in-the-CSF (cDSC)-MRI. At 4-hour-post-GBCA, the vitreous-body showed a trend of smaller enhancement area (55±11% versus 49±11%, P =.14) and lower GBCA-concentration (0.044±0.014 versus 0.028±0.010 mmol/L, P =.07) compared to immediate-post-GBCA. The intraorbital-optic-nerve showed more widespread enhancement (39±5% versus 59±6%, P =.01) and higher GBCA-concentration (0.023±0.009 versus 0.059±0.015 mmol/L, P <.001) at 4-hour-post-GBCA.
Abstract 5253: Molecular correlates of progression-free survival in recurrent gliomas treated with pembrolizumab
Kateb, Hussam Al, Campian, Jian L., Ensign, Shannon P. Fortin, Galanis, E., Hammack, J. E., Ida, Cristaine M., Klebig, Mitch L., Kaufmann, Timothy J., Moon, Autumn C., Mrugala, Maciej , Neth, Bryan J. , aPorter, Alyx B., Ruff, Michael W. , Sherman, Wendy J., Uhm, Joon H. , Kizilbash, Sani H., Ensign, Shannon P. Fortin , Neth, Byran J. , Ensign, Shannon P. Fortin , Shafqat, Shameel , Maqbool, Muhammad Asad , Al‐Kateb, Hussam , Burns, Terry C. , Campian, Jian , Hammack, Julie E., Ida, Cris, Klebig, Mitchell, Kaufmann, Timothy J. , Sener, Uğur , Sherman, Wendy, Vaubel, Rachael A. , Kizilbash, Sani H.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 5253-5253

10.1158/1538-7445.am2026-5253 Get It

Abstract Background: Pembrolizumab has been increasingly used off label for recurrent gliomas, yet biomarkers predicting response are poorly defined. Gliomas exhibit substantial molecular heterogeneity across Glioblastoma, IDH-wildtype (GBM), Astrocytoma, IDH-Mutant (A-IDHm), and Oligodendroglioma, 1p/19q co-deleted (OLIGO), which may influence immunotherapy efficacy. This study aimed to identify molecular predictors of progression-free survival (PFS) in recurrent glioma patients treated with pembrolizumab. Methods: Adults ≥18 years with recurrent glioma receiving ≥2 cycles of pembrolizumab between 2014 - 2024 were retrospectively identified across Mayo Clinic. Next-generation sequencing (NGS) reports were reviewed and archival tumor tissue resected prior to pembrolizumab initiation was analyzed when available. Comprehensive molecular profiling was performed using the Mayo Clinic Solid Tumor Panel which employs the Illumina Tru-Sight Oncology 500 High-Throughput NGS assay. Progression was assessed using RANO 2.0 criteria. Genomic alterations (clinically relevant sequences and/or copy-number variants) were evaluated using the Kaplan-Meier method, with differences in PFS compared using the log-rank test. Results: Thirty-three patients were included [median (range) age: 44.0 (21-76) years; 63.6% male]. The interval between tumor tissue sampling and pembrolizumab initiation was 9.9 (0.9-176.1) months, and median treatment duration was 2.8 (1.4-10.4) months. Median PFS for the overall cohort was 2.4 (0.8-15.2) months, and median overall survival from pembrolizumab initiation was 6.9 (0.9-48.2) months. Patients with OLIGO (n=8) had a longer PFS [4.6 (1.9-15.2) months] than either A-IDHm [n=11; PFS 2.1 (1.1-4.4) months] or GBM [n=14; PFS 2.3 (0.8-9.2) months]. Within OLIGO, CDKN2A/B heterozygous deletion (n=3) predicted a shorter PFS (3.9 vs 10.9 months; p=0.0462), while in A-IDHm, FANC mutation (n=2) was associated with a longer PFS (4.17 vs 1.61 months; p=0.0224). No significant associations with PFS were observed for other altered genes or pathways evaluated, including but not limited to Tumor Mutational Burden, EGFR, RB1, TP53, FUBP1, NF 1 or 2, PTEN, PDGFRA, PIK3CA, PIK3R1, CDK4, KRAS, MLH1, MLH2, MSH6 genomic alterations or CDKN2A/B homozygous deletion (all p&gt;0.05). Conclusions: Pembrolizumab shows limited overall efficacy in recurrent gliomas, however, exploratory analyses identified several subtype-specific genomic alterations that may correlate with PFS. These hypothesis-generating findings highlight the potential influence of underlying tumor biology on immunotherapy response and warrant further validation in larger, prospective cohorts. Citation Format: Shameel Shafqat, Muhammad Asad Maqbool, Hussam Al Kateb, Terry C. Burns, Jian L. Campian, Shannon P. Fortin Ensign, Evanthia Galanis, Julie E. Hammack, Cristaine M. Ida, Mitch L. Klebig, Timothy J. Kaufmann, Autumn C. Moon, Maciej M. Mrugala, Bryan J. Neth, Alyx B. aPorter, Michael W. Ruff, Ugur T. Sener, Wendy J. Sherman, Joon H. Uhm, Rachael A. Vaubel, Sani H. Kizilbash. Molecular correlates of progression-free survival in recurrent gliomas treated with pembrolizumab [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5253.
Abstract 4228: Validation of the CLL treatment infection model (CLL-TIM) in patients with newly diagnosed chronic lymphocytic leukemia (CLL)
Mwangi, Raphael , Shanafelt, Tait D. , Basnet, Soren, West, Emily L., Keegan, Owen, Call, Timothy G., Yuan, Yao, Vallejo, Bryan Alexis , Hampel, P., Wang, Yucai, Kenderian, Saad J., Achenbach, Sara J., Cerhan, James R., Hanson, CA, Slager, Susan L., Shanafelt, Tait D , Call, Timothy G., Hampel, Paul J. , Roeker, Lindsey E. , Achenbach, Sara J., Norman, Aaron D. , Rabe, Kari G. , Kay, Neil E. , Cerhan, James R. , Slager, Susan, Parikh, Sameer A.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 4228-4228

10.1158/1538-7445.am2026-4228 Get It

Abstract Prognostic indices such as the CLL International Prognostic Index (CLL-IPI) and the International Prognostic Score for Early-stage CLL (IPS-E) can predict time to first treatment (TTFT) in patients with early-stage CLL. Their ability to predict risk of infection - a leading contributor to morbidity and mortality in CLL - remains uncertain. The CLL-TIM is a machine-learning model developed in Europe that integrates clinical, laboratory, and infection-related data to predict TTFT or infection risk within 2-years of diagnosis, Receiver Operating Characteristic - Area Under the Curve (ROC-AUC) 0.74; Agius et al., Nat Comm 11, 363 2020. We conducted the first validation of CLL-TIM in a US cohort of newly diagnosed CLL patients and compared its performance with the CLL-IPI and IPS-E indices. Adults with newly diagnosed CLL (2000-2020) were identified through the Rochester Epidemiology Project using International Classification of Disease (ICD) codes; all diagnoses were confirmed. We replicated the variable selection from the original CLL-TIM model and applied it to our cohort. The primary endpoint was a 2-year composite of either TTFT or incident infection (defined as having blood cultures drawn). Model performance was evaluated using ROC-AUC consistent with the original CLL-TIM methods. CLL-IPI and IPS-E performance was assessed using time-dependent ROC-AUC; pairwise differences in discrimination were tested using DeLong. We identified 454 CLL patients with a median age of 72 years [range, 30-97], 166 (37%) were female, Rai Stage was 0-II in 399 (92%) patients. IGHV genes were unmutated in 130/305 (42%) patients and TP53 disruption (either del17p by FISH or TP53 mutation) was present in 24/329 (8%) patients. At 2-years, 55 (12%) patients received CLL therapy, and 56 (12%) patients had an infection. The 2-year composite endpoint was observed in 94 (21%) patients. The ROC-AUC was 0.74 (95% CI 0.68-0.80) for CLL-TIM, 0.69 for CLL-IPI (95% CI 0.63-0.75, p=0.11 compared to CLL-TIM) , and 0.68 for IPS-E (95% CI 0.62-0.74, p=0.02 compared to CLL-TIM). We also evaluated the ROC-AUC using all the prognostic models for each individual endpoints. The corresponding ROC-AUC for TTFT at 2 years were 0.79, 0.74, and 0.76 for CLL-TIM, CLL-IPI, and IPS-E, respectively; and for infection at 2 years were 0.68, 0.57, and 0.52, respectively. This is the first validation of the CLL-TIM in a US-based cohort of newly diagnosed CLL patients. Although the CLL-TIM model exceeded the minimally meaningful discrimination threshold (AUC &gt;0.7) for individual patient-level risk prediction, there was no statistical difference in AUC between CLL-TIM and CLL-IPI, suggesting either model can predict the composite endpoint at 2 years. Most of the observed discrimination was driven by prediction of TTFT rather than infection, underscoring the need to develop more infection-specific risk models for newly diagnosed CLL. Citation Format: Raphael Mwangi, Tait D. Shanafelt, Soren Basnet, Emily L. West, Owen Keegan, Timothy G. Call, Yao Yuan, Bryan Alexis Vallejo, Paul J. Hampel, Lindsey E. Roeker, Yucai Wang, Saad J. Kenderian, Sara J. Achenbach, Aaron D. Norman, Kari G. Rabe, Neil E. Kay, James R. Cerhan, Curtis A. Hanson, Susan L. Slager, Sameer A. Parikh. Validation of the CLL treatment infection model (CLL-TIM) in patients with newly diagnosed chronic lymphocytic leukemia (CLL) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4228.
Abstract 5051: A multi-center hospital-based case-control study of lymphoid and myeloid neoplasms (AsiaLymph): Study design and initial findings for education, body mass index, and family history
Lan, Qing, Chan, John K., Lam, Tai Hing , Chen, Kexin, Kwong, Yok Lam, Xu, Caigang , Chiu, Brian CH, Liang, Raymond , Dennis, Ip, Hu, Wei, Bassig, Bryan A. , Purdue, Mark, Xu, Jun, Locke, Sarah J. , Wang, Sophia S., Berndt, Sonja, Hofmann, Jonathan N., Shi, Jianxin , Yu, Kai, Gadalla, Shahinaz, Jones, Rena, Dai, Hongji, Lyu, Zhangyan, Qiu, Lugui , Liu, Wei, zhang, huilai, Wang, Xianhuo, Chanock, Stephen, Linet, Martha, Vermeulen, Roel, Rothman, Nathaniel, Lan, Qing , Hurwitz, Lauren M. , Chan, John K.C., Chen, Kexin , Chiu, Brian C.‐H. , Cerhan, James R. , Hofmann, Jonathan N. , Gadalla, Shahinaz M. , McReynolds, Lisa J. , Jones, Rena R. , Qiu, Lugui , Liu, Wei , Zhang, Huilai , Wang, Xianhuo , Morton, Lindsay M. , Linet, Martha S. , Friesen, Melissa C. , Vermeulen, Roel , Rothman, Nathaniel

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 5051-5051

10.1158/1538-7445.am2026-5051 Get It

Abstract Background: Epidemiologic and other studies have identified environmental, occupational, and genetic risk factors for lymphoid and myeloid malignancies, but most studies have been conducted in Western populations. Investigations in populations with differing exposure patterns, distributions of disease subtypes, and genetic architecture are needed to fully understand hematopoietic tumor etiology. Methods: We conducted a large, multicenter, hospital-based case-control study of lymphoid and myeloid neoplasms in East Asia (AsiaLymph), including 5,671 lymphoid cases, 1,879 myeloid cases, and 3,858 controls. Participants completed a computer-assisted personal interview and provided biospecimens. Cases underwent central pathology review and were coded into the WHO Classification. Herein, we describe the study methods in detail and report association results for education, body mass index, and family history. Results: Greater BMI at age 20 but not at age 40 was associated with odds of total lymphoid neoplasm (per 5 kg/m2 increase: OR [95% CI]: 1.18 [1.09-1.27]), total myeloid neoplasm (OR [95% CI]: 1.17 [1.05-1.29]), and several subtypes. Greater educational attainment was associated with increased odds of total lymphoid neoplasm (for college vs. less than primary education: OR [95% CI]: 1.41 [1.21-1.65]) but not myeloid neoplasm (OR [95% CI]: 1.17 [0.95-1.45]; p-heterogeneity=0.02). There were also positive associations between family history of hematologic cancer in first degree relatives and odds of lymphoid neoplasm (OR [95% CI]: 1.53 [1.15-2.03]) and myeloid neoplasm (OR [95% CI]: 1.65 [1.11-2.44]) and specific subtypes. None of the evaluated risk factors were associated with NK/T-cell lymphoma, which supports a distinct etiology for this subtype. Conclusion: The AsiaLymph Study is one of the largest molecular epidemiology studies of both lymphoid and myeloid neoplasms with standardized World Health Organization classification of histopathologic subtypes and will serve as a valuable resource for etiologic investigations into risk factors for these malignancies. Citation Format: Qing Lan, Lauren M. Hurwitz, John K. Chan, Tai Hing Lam, Kexin Chen, Yok Lam Kwong, Xu Caigang, Brian CH Chiu, Raymond Liang, Ip Dennis, Wei Hu, Bryan Bassig, Mark Purdue, Jun Xu, Sarah Locke, Sophia S. Wang, James R. Cerhan, Sonja Berndt, Jonathan N. Hofmann, Jianxin Shi, Kai Yu, Shahinaz Gadalla, Lisa J. McReynolds, Rena Jones, Hongji Dai, Zhangyan Lyu, Lugui Qiu, Wei Liu, Huilai Zhang, Xianhuo Wang, Lindsay M. Morton, Stephen Chanock, Martha Linet, Melissa C. Friesen, Roel Vermeulen, Nathaniel Rothman. A multi-center hospital-based case-control study of lymphoid and myeloid neoplasms (AsiaLymph): Study design and initial findings for education, body mass index, and family history [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5051.
Abstract 1184: IHC-based prognostic sub-stratification of ovarian endometrioid carcinoma.
Taengwa, Gamaliel , Atkinson, Hunter J., McCauley, Bryan M. , Armasu, Sebastian M. , Wang, Chen, Doherty, Jennifer A., Goode, Ellen L. , Köebel, Martin, Atkinson, Hunter J., Doherty, Jennifer A. , Harris, Holly R. , Winham, Stacey J.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 1184-1184

10.1158/1538-7445.am2026-1184 Get It

Abstract Ovarian endometrioid carcinoma (OEC) is the second most common histotype associated with the most favorable prognosis among ovarian carcinomas. Similar to endometrial carcinoma, OEC exhibit significant molecular diversity. We aimed to develop a practical immunohistochemical (IHC) prognosticator by integrating IHC biomarkers with clinical substage, and surgical outcomes. This multi-institutional study included participants with primary invasive OEC from the Alberta Cancer Registry (AOVT), Mayo Clinic, and Disease of the Ovary and their Evaluation Study (DOVE). Pathology review excluded misclassified high-grade serous and mesonephric carcinomas leaving 422 OEC cases (AOVT N=158; DOVE N=143; Mayo N=121) with available tumor biospecimens who did not receive neoadjuvant treatment. Clinical characteristics included age, stage, grade, residual disease and 5-year survival. Clinical risk group was defined by combining stage and residual disease: Low (FIGO stage IA/IB & no macroscopic disease), Intermediate (stage IC-II& no macroscopic disease), High (stage III/IV or macroscopic disease). Tissue microarrays were stained for TP53, PMS2, MSH6, PGR, and CTNNB1 using IHC and were scored by a single pathologist. Tumors were hierarchically categorized as TP53-abnormal (TP53abn)/PGR-loss, mismatch-repair deficient (MMRd, via PMS2 and MSH6), nuclear-CTNNB1 (nCTNNB1), or no-specific-immunohistochemical-profile (NSIP). Overall survival (OS) at 5 years was compared across clinical risk and biomarker groups using Cox regression, adjusted for age and site to generate hazard ratios (HR), and 5-year survival rates (5-YSR). High clinical risk group was associated with worse 5-year OS compared to low & intermediate risk (p&lt;0.0001). Hierarchical IHC biomarker groups were also associated with 5-year OS, adjusted for age and study site (p&lt;0.0001), with consistently worse survival for combined TP53abn/PGR-loss (n=17, HR=6.07, 95% CI 2.78-13.26), PGR-loss only (n=55, HR=4.17, 95% CI 2.19-7.94), TP53abn only (n=29, HR=2.04, 95% CI 0.85-4.90), and better survival for nuclear-CTNNB1 (n=146, HR=0.22, 95% CI 0.07-0.65) compared to NSIP (n=132). Within the low-risk group, MMRd, nCTNNB1, or NSIP had greater than 97% 5-YSR, while OEC with TP53abn/PGR-loss or PR-loss only had less than 75% 5-YSR. Within the intermediate group, only nCTNNB1 exceeded a 5-YSR of greater than 97%. Within the high-risk group, 5YSR for nCTNNB1 OEC was 90.9%, compared to only 16.7% for TP53abn/PGR-loss. This IHC-based algorithm refines prognosis beyond clinical substage. It identifies low-risk patients with unfavorable prognosis (TP53abn/PGRloss, PGR loss only) who may benefit from adjuvant therapy, and also patients with favorable prognosis within the intermediate group for whom adjuvant therapy could be de-escalated. Further patient selection for chemo vs. hormone therapy in the high-risk group may be improved by biomarkers. Citation Format: Gamaliel Taengwa, Hunter J. Atkinson, Bryan M. McCauley, Sebastian M. Armasu, Chen Wang, Jennifer A. Doherty, Holly R. Harris, Ellen L. Goode, Martin Koebel, Stacey J. Winham. IHC-based prognostic sub-stratification of ovarian endometrioid carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1184.
Non-Typhoidal Salmonella enterica Bacteremia Complicated by Native Shoulder Septic Arthritis in a Patient with Sickle Cell Disease Following Foodborne Exposure: A Case Report and Literature Review
Godart, Gabriel A. , Yadav, Vidit , Springer, Bryan D. , Durvasula, R, Elwasila, Sammer M., Oring, Justin , Godart, Gabriel , Bestic, Joseph M. , Oring, Justin , Schoch, Bradley S. , Elwasila, Sammer M

Mayo Clinic

Infectious Disease Reports | April 2, 2026 | Volume: 18 | Issue: 2 | Pages: 30

10.3390/idr18020030 | PMID 42042319 Get It

Background/Objectives: Non-typhoidal Salmonella (NTS) species are well-recognized causes of invasive infection in patients with sickle cell disease (SCD), with a particular predilection for the musculoskeletal system. Although Salmonella osteomyelitis is well described in this population, septic arthritis is uncommon, especially involving the shoulder joint. We describe a case of NTS bacteremia complicated by native shoulder septic arthritis in a patient with SCD and review its clinical implications. Methods: We report the clinical course, diagnostic evaluation, microbiologic findings, imaging studies, and management of a 22-year-old man with homozygous SCD who presented with a vaso-occlusive pain crisis and subsequently developed severe sepsis with persistent Salmonella enterica bacteremia following ingestion of undercooked poultry. Persistent bacteremia prompted further evaluation for metastatic infection using advanced imaging and diagnostic arthrocentesis. Results: Whole-body imaging identified septic arthritis of the native right shoulder, which was confirmed by synovial fluid cultures growing Salmonella species. The patient underwent arthroscopic irrigation and debridement for source control. Antimicrobial therapy was narrowed to intravenous ceftriaxone based on susceptibility data and continued for six weeks. The patient demonstrated clinical improvement with resolution of bacteremia and was discharged to rehabilitation to complete therapy. Conclusions: This case highlights the importance of a careful exposure history, including foodborne sources, in patients with SCD presenting with invasive Salmonella infection. Persistent bacteremia should prompt early investigation for metastatic foci, and timely surgical source control combined with targeted antimicrobial therapy is essential for optimal outcomes in this population.
One-Stage Versus Two-Stage Exchange Arthroplasty for Periprosthetic Joint Infection
Fehring, Thomas K. , Otero, Jesse E. , Fehring, Keith A. , Curtin, Brian M. , Springer, Bryan D. , Valle, Craig J. Della, Parvizi, Javad , Hietpas, Kayla , Ready, Alexis , Odum, Susan M. , Group, the PJI Study, Parvizi, Javad , Springer, Bryan D. , Valle, Craig J. Della

Mayo Clinic

Journal of Bone and Joint Surgery | April 1, 2026 | Volume: 108 | Issue: 14 | Pages: 1070-1082

10.2106/jbjs.25.00713 | PMID 41921050 Get It

Background: A 2-stage approach is most commonly used to treat periprosthetic joint infection (PJI). Some successful studies of the 1-stage approach were underpowered, lacked a 2-stage comparative group, and excluded patients with draining sinuses, comorbidities, and/or antibiotic-resistant organisms. Given the morbidity and expense associated with 2-stage treatment, we conducted a prospective, multicenter, randomized trial to compare the results of 1- and 2-stage PJI treatment, specifically including patients with draining sinuses, comorbidities, and resistant organisms. Methods: Patients presenting for surgical treatment of a chronic PJI with a known organism following primary total hip or knee arthroplasty were included (with infection defined by Musculoskeletal Infection Society [MSIS] criteria). Patients with prior revision, culture-negative infection, or fungal infection, or who were immunosuppressed or had soft-tissue involvement precluding wound closure, were excluded. Patients were classified according to the McPherson host staging system. Clinical success was defined as (1) no clinical failure or reinfection with the same or new organism; (2) no reoperation for PJI; and (3) no PJI-related death. A double-instrument setup was used for all patients, as were similar irrigation and antibiotic protocols. A total of 323 patients (166 one-stage; 157 two-stage) were randomized. Groups were similar with respect to demographics and host classification. After excluding patients who died or were lost to follow-up, 258 of the 323 patients had 2-year follow-up (135 one-stage and 123 two-stage). The rate of patient loss to follow-up was similar between the treatment groups. Results: Sixteen patients in the 1-stage group and 9 patients in the 2-stage group died prior to 2-year follow-up. Overall, the 2-year success rate of 1-stage treatment was 97% (131 of 135), while the success of 2-stage treatment was 91% (112 of 123) (p = 0.04). Compared with the 2-stage group, the 1-stage group had 3-times the odds of overall success in a regression analysis (unadjusted odds ratio = 3.22 [95% confidence interval = 1.0 to 10.38]). After adjusting for specific variables (McPherson host grade, resistant organism, and draining sinuses), 1-stage treatment also had 3-times the odds of success. Conclusions: The results of this prospective randomized trial indicated that 1-stage treatment (97% success) was statistically noninferior to 2-stage treatment (91% success) when treating chronic PJI following primary total hip or knee arthroplasty, provided the protocols described here are explicitly followed. Extrapolation to other patient cohorts and clinical situations should be avoided. Level of Evidence: Therapeutic Level I . See Instructions for Authors for a complete description of levels of evidence.
Establishment of a canine urothelial carcinoma‐derived organoid biobank: A platform for comparative and translational research
Zdyrski, Christopher , Pawlak, Aleksandra , Nicholson, Hannah, Corbett, Megan P. , Catucci, M., Cheville, John, Cho, H, Melvin, Bryan J. , Peng, Jiayi, Saba, Corey , Hamsher, Hayden, Friedenberg, Steven G. , Mochel, Jonathan P. , Nicholson, Hannah F , Woodward, Andrew P , Douglass, Eugene , Mochel, Jonathan P , Allenspach, Karin , Zdyrski, Christopher , Pawlak, Aleksandra , Cheville, John C.

Mayo Clinic

Clinical and Translational Medicine | March 27, 2026 | Volume: 16 | Issue: 4 | Pages: No page available

10.1002/ctm2.70645 | PMID 41889014 Get It

Thirty-Six-Month Multicentre Outcomes of Combined Phacoemulsification and Hydrus Microstent Implantation in Eyes With Normal Tension Glaucoma
Ang, Bryan Chin Hou, Sim, Jackie Jia Lin , Chua, Chun Hau, Khairy, Thomas, Salimi, Ali , Harasymowycz, Paul , Ang, Bryan Chin Hou , Ang, Bryan C H , Salimi, Ali , Betzler, Bjorn Kaijun , Ramanathan, Rajesh, Hong, Ashley Shuen Ying

Mayo Clinic

Journal of Glaucoma | March 26, 2026 | Volume: 35 | Issue: 6 | Pages: 369-376

10.1097/ijg.0000000000002709 | PMID 41934671 Get It

Precis: This retrospective multicentre study of 77 NTG eyes undergoing phacoemulsification and Hydrus implantation showed a sustained reduction in medication burden, while maintaining IOP levels. Complications were rare and nonsight-threatening. Purpose: To evaluate 36-month outcomes of combined phacoemulsification and Hydrus Microstent implantation (Phaco-Hydrus) in eyes with normal tension glaucoma (NTG). Methods: This multicentre retrospective study included 77 NTG eyes from Singapore and Canada that underwent Phaco-Hydrus between 2014 and 2023. Primary outcomes were changes in intraocular pressure (IOP) and medication burden, and cumulative success probabilities from Kaplan-Meier (KM) analyses. Longitudinal changes were analysed using generalized estimating equations. Results: Of 77 eyes, 31 completed 36 months of follow-up. Mean baseline IOP and medications was 13.5±2.5 mm Hg and 1.7±0.9, respectively. No significant reductions in IOP were observed. A sustained reduction in medication use was observed at all follow-up timepoints ( P ≤0.001). At 36 months, medication use decreased by −0.7±0.2 [adjusted mean difference±SE of the mean [SEM]]. Proportion of medication-free eyes increased from 7.8% (n=6/77) at baseline to 45.2% (n=14/31) at 36 months. Cumulative success probabilities varied widely based on definitions. When defined as a decrease in ≥1 medication from baseline without an increase in IOP, or IOP ≤15 mm Hg and reduced ≥20% from baseline while medication-free, and no additional laser or incisional glaucoma surgery, this was 40.7% at 36 months. No visual field mean deviation progression was detected. Adverse events were infrequent and nonsight-threatening. Conclusion: In eyes with NTG, Phaco-Hydrus may offer a greater role in medication reduction or achieving a medication-free status over 36 months, rather than absolute IOP reduction.
Histologic and immunohistochemical characterization and frequency of rare subtypes of canine invasive urothelial carcinoma
Corbett, Megan P. , Elbadawy, Mohamed , Cheville, J., Wickham, Hannah , Nicholson, Hannah, Catucci, M., Melvin, Bryan J. , Ahmed, Basant H. , Zdyrski, Christopher , Oliveira, Lilian, Howerth, Elizabeth W. , Fasina, Olufemi , Mochel, Jonathan P. , Woodward, Andrew P , Nicholson, Hannah F , Catucci, Michael , Melvin, Bryan J , Zdyrski, Christopher , Howerth, Elizabeth W , Pawlak, Aleksandra , Fasina, Olufemi , Mochel, Jonathan P , Pawlak, Aleksandra , Allenspach, Karin

Mayo Clinic

Veterinary Pathology | March 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/03009858261428496 | PMID 41879030 Get It

While most cases of human muscle-invasive bladder cancer (MIBC) are diagnosed as conventional urothelial carcinoma (UC), there is growing recognition of histologic subtypes and divergent differentiation within conventional UC. In this study, 31 dogs with UC (33 slides) were evaluated for histologic subtypes and divergent differentiation, as specified by the recent World Health Organization update on the classification of urinary bladder cancers. Slides were reviewed by a medical uropathologist and 3 board-certified veterinary pathologists and assessed for expression of uroplakin III, vimentin, and E-cadherin. All tumors were classified as UC. Fifteen cases were identified as conventional UC. Among the remainder, 8 displayed glandular differentiation, 4 were classified as sarcomatoid UC, 2 showed squamous differentiation, 1 case was classified as a large nested subtype, and 1 case was classified as a tubular/microcystic subtype. This study found a higher frequency of certain histologic subtypes and divergent differentiation in canine UC, particularly sarcomatoid UC and UC with glandular differentiation, compared to previous reports of both canine UC and human MIBC. The relatively high prevalence of the sarcomatoid UC and UC with glandular differentiation in dogs observed in this study suggests that canine UC may serve as a valuable translational model for evaluating novel therapeutic agents, particularly for these rare and aggressive subtypes in humans.